Target-Based Screening Against eIF4A1 Reveals the Marine Natural Compound Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Anti-Tumor Activity.

CONCLUSIONS: Elatol's identification as an eIF4A1 inhibitor with in vivo anti-tumor activities provides proof-of-principle for target-based screening against this highly promising target for cancer therapy.
PMID: 29844128 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 29, 2018 Category: Cancer & Oncology Authors: Peters TL, Tillotson J, Yeomans AM, Wilmore S, Jiménez-Romero C, Amador LA, Amin AD, Li L, Pongtornpipat P, Zerio CJ, Paine-Murrieta G, Vega F, Packham G, Rodriguez AD, Chapman E, Schatz JH, Benes CH, Greninger P, Lemm E, Ambrose AJ Tags: Clin Cancer Res Source Type: research